Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ryvu Therapeutics's total inventories for the quarter that ended in Mar. 2026 was zł1.34 Mil. Ryvu Therapeutics's average total inventories from the quarter that ended in Dec. 2025 to the quarter that ended in Mar. 2026 was zł1.34 Mil.
In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Ryvu Therapeutics's Net-Net Working Capital per share for the quarter that ended in Mar. 2026 was zł-3.10.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Ryvu Therapeutics's Days Inventory for the
three
months ended in Mar. 2026 was 29.49.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Ryvu Therapeutics's Inventory Turnover for the quarter that ended in Mar. 2026 was 3.09.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Ryvu Therapeutics's Inventory-to-Revenue for the quarter that ended in Mar. 2026 was 0.08.
Ryvu Therapeutics (WAR:RVU) Total Inventories Explanation
Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.
1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.
Ryvu Therapeutics's Net-Net Working Capital Per Share for the quarter that ended in Mar. 2026 is
4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Ryvu Therapeutics's Inventory to Revenue for the quarter that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.
When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.
Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.
Ryvu Therapeutics Total Inventories Related Terms
Ryvu Therapeutics Total Inventories Historical Data
* Premium members only.
The historical data trend for Ryvu Therapeutics's Total Inventories can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.
Ryvu Therapeutics (WAR:RVU) has a Total Inventories of zł1.34 Mil as of Mar. 2026. The total amount of inventory as recorded on a company's balance sheet. View historical data for Ryvu Therapeutics and its competitors.
Is Ryvu Therapeutics' Total Inventories too high?
Ryvu Therapeutics' current Total Inventories is zł1.34 Mil. Overall, Ryvu Therapeutics has a GF Score™ of 66/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Ryvu Therapeutics' Total Inventories compare to VRTX and REGN?
Ryvu Therapeutics' Total Inventories of zł1.34 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Inventories for a Biotechnology company?
A good Total Inventories depends on the Biotechnology industry context. However, Total Inventories should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Inventories mean?
A high Total Inventories can signal that a stock is expensive relative to its fundamentals. The total amount of inventory as recorded on a company's balance sheet. View historical data for Ryvu Therapeutics and its competitors. Ryvu Therapeutics's current Total Inventories is zł1.34 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ryvu Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Ryvu Therapeutics (WAR:RVU) is currently considered Possible Value Trap. The stock's GF Value™ is zł45.84, compared to a current price of zł14.98 — trading 67.3% below its estimated fair value. The current Total Inventories is zł1.34 Mil. Ryvu Therapeutics' overall GF Score™ is 66/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Inventories calculated?
Total Inventories is calculated from a company's financial statements. For Ryvu Therapeutics (WAR:RVU), the current Total Inventories is zł1.34 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ryvu Therapeutics (WAR:RVU) Overvalued in 2026?
Based on GuruFocus' analysis, Ryvu Therapeutics stock appears to be undervalued.
The current stock price of zł14.98 is trading 67.3% below its estimated GF Value™ of zł45.84.
GuruFocus considers Ryvu Therapeutics to be Possible Value Trap.
Key valuation signals for WAR:RVU:
Total Inventories: zł1.34 Mil
GF Value™: zł45.84 vs. price of zł14.98 (67.3% below fair value)
No single metric tells the full story. See the WAR:RVU stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ryvu Therapeutics SA is a company which is engaged in discovering and developing small molecule therapies that address oncology. Its product candidate SEL120, is a kinase inhibitor with potential for development in hematological malignancies and solid tumors. The pipeline products of the company are developed in the areas of kinases, cancer metabolism, synthetic lethality, and immuno-oncology pathways.
66GF Score
Get the complete analysis for WAR:RVU
Total Inventories is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WAR:RVU has been successfully added to your 
